Life Biosciences, a Boston longevity biotech co-founded by Harvard genetics professor David Sinclair, has locked down an $80 ...

Funding to support the Phase 1 clinical trial of ER-100 in optic neuropathies and further investigation of new candidates from the company’s Partial Epigenetic Reprogramming platform ...

Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in ...

Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...

Kazia Therapeutics is paying $1.4 million upfront to secure a platform for generating epigenetic drugs from an Australian research institute. Brisbane-based QIMR Berghofer develop ...

A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

India, April 13 -- Life Biosciences, a clinical-stage biotechnology company focused on reversing diseases of aging, has ...

Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain malignancy, and create “transcriptional addiction” in cancer. They function via ...

Protease hypersensitivity leaves lasting immune memory in lung tissue, influencing future inflammation. Read more.

What if sound waves succeed where drugs failed? Focused ultrasound shows promise in treating Alzheimer's-safe, effective, and ...

From lifestyle habits to emotional support, the absence of marriage or a partner may quietly influence cancer risk in ways we’re only beginning to understand.

The Beijing biotech has been set up to tap into the growing interest in macrocyclic peptides as an emerging treatment ...